Flucelvax Tetra Injektionssuspension

Land: Schweiz

Sprache: Deutsch

Quelle: Swissmedic (Swiss Agency for Therapeutic Products)

Wirkstoff:

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018), haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018), haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage))

Verfügbar ab:

Medius AG

ATC-Code:

J07BB02

INN (Internationale Bezeichnung):

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018), haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018), haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage))

Darreichungsform:

Injektionssuspension

Zusammensetzung:

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018) 15 µg, haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013-like: reassortant from B/Singapore/INFTT-16-0610/2016 (Yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, natrii dihydrogenophosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.7 mg, kalium 0.1 mg, residui: polysorbatum 80, cetrimidum, propiolactonum.

Klasse:

B

Therapiegruppe:

Impfstoffe

Therapiebereich:

aktive Immunisierung gegen Influenza , ab 9 Jahren

Berechtigungsstatus:

zugelassen

Berechtigungsdatum:

2021-05-04